← Stoke Therapeutics, Inc. (STOK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Stoke Therapeutics, Inc. (STOK)
Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Stoke Therapeutics (STOK) is a ~$1.8B market-cap rare-disease biotech with 128 employees whose entire investment case pivots on zorevunersen, a Phase 3 antisense oligonucleotide (mechanism not disclosed in available data) targeting Dravet Syndrome. The company reported $184M in 2025 revenue—a sharp jump from $37M in 2024—against only a $7M net loss, though R&D spend of $138M signals the revenue likely includes non-recurring collaboration income. With ~7.7 months of cash runway and a pivotal Phase 3 readout expected around March 2027, STOK is a high-conviction binary event play.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 3 · zorevunersenimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| STK-001 - Single Ascending Doses | Phase 2 | Dravet Syndrome |
| zorevunersen | Phase 3 | Dravet Syndrome |
| STK-001 | Phase 2 | Dravet Syndrome |
Price & technical context
3-month
-19.7%
6-month
-17.9%
12-month
+11.7%
52-wk range
$22.37–$38.35
vs 50-day MA
-12.4%
vs 200-day MA
-17.1%
Realized vol
59.1%
Max drawdown
-62.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for STOK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.